Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

A team of pharmaceutical researchers at Novartis Biomedical Research, working with an international team of associates, has ...

The Lancet Respiratory Medicine published a phase 2 clinical study article on China's first DPP-1 inhibitor, HSK31858, led by ...

Research reveals how specific sleep stages protect brain vulnerable to Alzheimer's, offering hope through simple lifestyle ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier ...

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...

Demolition works as part of preparations for the second phase of the Liverpool Health and Academic Precinct (LHAP) redevelopment of Liverpool Hospital will begin this month.

AstraZeneca and the Memorial Sloan Kettering Cancer Center (MSK) have tapped digital health tech company IgniteData to ...

Tourmaline Bio's Pacibekitug shows promise in IL-6 targeting for autoimmune diseases. Learn about its potential and ongoing trials. Read why TRML is a hold.